

# Drivers of Positive Health Technology Assessment Outcomes for Oncology Drugs in Three Global Markets

## A comprehensive review

Norwood-Knutsson, Caitlin

GlobalData, London, United Kingdom

### Objectives

To determine the key drivers and considerations influencing Health Technology Assessment (HTA) outcomes for oncology drugs in Australia, Canada, and the United Kingdom (UK), to provide insight into reimbursement pathways and alleviate uncertainties during the appraisal process across three national HTA agencies.


### Methods

A comprehensive review of all HTA assessments conducted for marketed oncology drugs between January 2022 and June 2023 in respective markets was identified. By leveraging literature reviews of appraisal recommendations, common factors influencing HTA decision making were assessed to categorize positive, negative, and neutral outcomes.


### Results

Of the 152 HTA assessments identified, the most influential factors that influence HTA outcomes were clinical efficacy, economic implications, and disease-related factors.

**Figure 1: Framework for identifying and filtering HTA assessments**




**Figure 2: Distribution of positive, negative and neutral outcomes for oncology drugs across markets**



#### Key Takeaways:

- In Australia, 56% of outcomes were positive**, influenced by clinical efficacy (44%), economic implications (36%) & disease-related factors (20%).
- Canada's outcomes were primarily neutral (87%)** - recommended with restrictions - due to underlying cost-considerations. However, clinical efficacy (81%) and disease-related factors (15%) were the significant drivers for the recommendation.
- UK demonstrated the highest proportion of positive outcomes overall (64%)** driven by clinical efficacy (50%), disease-related factors (29%) & economic implications (21%).
- 67% of cases irrespective of the outcome were attributed to clinical efficacy, which can be further segregated into clinical evidence acceptability (57%), comparative efficacy (41%), and comparator choice (>2%).

**Figure 3: Key drivers influencing HTA outcomes by country**



### Conclusions

While HTA agencies exhibit divergent priorities within different markets, the study reveals commonalities in the factors forming the basis for decision-making, namely that the clinical dimension is still a key factor in assessments. Navigating the distinctive socio-political and population-specific needs of each market poses challenges for manufacturers to tailor strategies effectively. By accounting for HTA outcome drivers, stakeholders can better navigate the complex landscape more successfully to ensure improved access to oncology treatments.